Patents/Inventors

Liangxing Wu

Wilmington, DEUS34 patents

41 Patents

US125344632026
Substituted Tricyclic Compounds as FGFR Inhibitors
Incyte Holdings Corporation
0 cites
US124668222025
Heterocyclic Compounds as Immunomodulators
Incyte Corporation
0 cites
US124668282025
Bicyclic Amines as CDK2 Inhibitors
Incyte Corporation
0 cites
US124417312025
Pyrazolopyrimidine Compounds and Uses Thereof
Incyte Corporation
0 cites
US123123312025
Imidazolyl Pyrimidinylamine Compounds as CDK2 Inhibitors
Incyte Corporation
0 cites
US122470262025
Heterocyclic Compounds as Immunomodulators
Incyte Corporation
0 cites
US122470382025
Pyrido[3,2-d]pyrimidine Compounds as Immunomodulators
Incyte Corporation
0 cites
US121877252025
Tricyclic Urea Compounds as JAK2 V617F Inhibitors
Incyte Corporation
0 cites
US121877432025
Heterocyclic Compounds as Immunomodulators
Incyte Corporation
0 cites
US121292672024
Heteroaryl Amide Compounds as Sting Activators
Incyte Corporation
0 cites
US120604332024
CD73 Inhibitor and A2A/A2B Adenosine Receptor Inhibitor Combination Therapy
Incyte Corporation
0 cites
US120308892024
Imidazopyridazine and Imidazopyridine Compounds and Uses Thereof
Incyte Corporation
0 cites
US119997402024
Fused Pyrazine Derivatives as A2A / A2B Inhibitors
Incyte Corporation
0 cites
US119816712024
Bicyclic Pyrazolyl Amines as CDK2 Inhibitors
Incyte Corporation
0 cites
US119588612024
Spirocyclic Lactams as JAK2 V617F Inhibitors
Incyte Corporation
0 cites
US119199042024
Sulfonylamide Compounds as CDK2 Inhibitors
Incyte Corporation
0 cites
US119199082024
Substituted Pyrrolo[2,3-d]pyrimidine Compounds as JAK2 V617F Inhibitors
Incyte Corporation
0 cites
US119127222024
Tricyclic Heteroaryl Compounds as Sting Activators
Incyte Corporation
0 cites
US118733042024
Fused Pyrimidine Derivatives as A2A/A2B Inhibitors
Incyte Corporation
0 cites
US118733092024
Heterocyclic Compounds as Immunomodulators
Incyte Corporation
0 cites
US118664322024
Dihydropyrido[2,3-d]pyrimidinone Compounds as CDK2 Inhibitors
Incyte Corporation
0 cites
US118664352024
Heterocyclic Compounds as Immunomodulators
Incyte Corporation
0 cites
US118514262023
Bicyclic Amines as CDK2 Inhibitors
Incyte Corporation
0 cites
US118405342023
Substituted Tricyclic Compounds as FGFR Inhibitors
Incyte Holdings Corporation
0 cites
US118405462023
Imidazopyridazine Compounds and Uses Thereof
Incyte Corporation
0 cites
US117877932023
Heterocyclic Compounds as Immunomodulators
Incyte Corporation
0 cites
US117808402023
Tricyclic Urea Compounds as JAK2 V617F Inhibitors
Incyte Corporation
0 cites
US117673232023
Tricyclic Pyridone Compounds as JAK2 V617F Inhibitors
Incyte Corporation
0 cites
US117534132023
Substituted Pyrrolo[2,1-f][1,2,4]triazine Compounds as JAK2 V617F Inhibitors
Incyte Corporation
0 cites
US117186052023
Heterocyclic Compounds as Immunomodulators
Incyte Corporation
0 cites
US117133172023
Tricyclic Heterocyclic Compounds as Sting Activators
Incyte Corporation
0 cites
US116919712023
Naphthyridinone Compounds as JAK2 V617F Inhibitors
Incyte Corporation
0 cites
US116738832023
Heterocyclic Compounds as Immunomodulators
Incyte Corporation
0 cites
US116738942023
Imidazopyrimidines and Triazolopyrimidines as A2A / A2B Inhibitors
Incyte Corporation
0 cites
US116676352023
Bicyclic Heterocycles as FGFR4 Inhibitors
Incyte Holdings Corporation
0 cites
US116614222023
Tricyclic Urea Compounds as JAK2 V617F Inhibitors
Incyte Corporation
0 cites
US116135362023
Heterocyclic Compounds as Immunomodulators
Incyte Corporation
0 cites
US116083372023
Heterocyclic Compounds as Immunomodulators
Incyte Corporation
0 cites
US115966922023
PD-L1/STING Conjugates and Methods of Use
Incyte Corporation
0 cites
US115723662023
Heterocyclic Compounds as Immunomodulators
Incyte Corporation
0 cites
US115660262023
Heterocyclic Compounds as Immunomodulators
Incyte Corporation
0 cites